The company focuses on treating bone metabolism disorders by developing injectable biomaterials combined with active ingredients to prevent fractures caused by osteoporosis. Their goal is to provide options for the treatment of bone voids and lesions through a pipeline of advanced biomaterials. In November 2021, Biologics 4 Life was acquired by Graftys, although the terms of the transaction were not disclosed.